Reported 2 days ago
Novo Nordisk, known for its successful weight-loss drug Wegovy, may see its impressive sales growth come to a halt amid weak prescription data and increased competition from Eli Lilly's Zepbound. Analysts predict a possible reduction in sales guidance for 2025, raising concerns over the company's market value, which has already dropped significantly since late last year. With the FDA addressing supply issues, uncertainty remains about whether Novo can retain its market position against rising rivals.
Source: YAHOO